Skip to main content
Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes.
A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.
Renal dysfunction in patients with thalassaemia.
Red cell alloimmunization in a diverse population of transfused patients with thalassaemia.
The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America.
Advances in clinical research in sickle cell disease.
Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis.
Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.